Magali Waelbroeck

List of Publications by Year
in descending order

68	2,383	186265 28	206112 48
papers	citations	h-index	g-index

68	68	68	1124
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method. Peptides, 2011, 32, 1593-1599.	2.4	18
2	Mutational and Cysteine Scanning Analysis of the Glucagon Receptor N-terminal Domain. Journal of Biological Chemistry, 2010, 285, 30951-30958.	3.4	16
3	An alternative presentation of metabolism. Biochemistry and Molecular Biology Education, 2007, 35, 233-237.	1.2	0
4	Techniques: Promiscuous GÎ± proteins in basic research and drug discovery. Trends in Pharmacological Sciences, 2005, 26, 595-602.	8.7	125
5	G protein activation by G protein coupled receptors: ternary complex formation or catalyzed reaction?. Biochemical Pharmacology, 2004, 68, 799-806.	4.4	40
6	Allosteric drugs acting at muscarinic acetylcholine receptors. Neurochemical Research, 2003, 28, 419-422.	3.3	7
7	Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor. Biochemical Journal, 2003, 370, 1003-1009.	3.7	2
8	Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue. Biochemical Journal, 2002, 362, 389-394.	3.7	35
9	Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligandâ€™s third residue. Biochemical Journal, 2002, 362, 389.	3.7	33
10	VPAC1 receptors have different agonist efficacy profiles on membrane and intact cells. Cellular Signalling, 2002, 14, 689-694.	3.6	5
11	Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity. FEBS Journal, 2002, 269, 3211-3219.	0.2	6
12	A Small Sequence in the Third Intracellular Loop of the VPAC1 Receptor Is Responsible for Its Efficient Coupling to the Calcium Effector. Molecular Endocrinology, 2002, 16, 1089-1096.	3.7	8
13	Two Basic Residues of the h-VPAC1 Receptor Second Transmembrane Helix Are Essential for Ligand Binding and Signal Transduction. Journal of Biological Chemistry, 2001, 276, 1084-1088.	3.4	60
14	Activation of Guanosine 5â€²-[Î³-³⁵S]thio-triphosphate Binding through M₁Muscarinic Receptors in Transfected Chinese Hamster Ovary Cell Membranes: 1. Mathematical Analysis of Catalytic G Protein Activation. Molecular Pharmacology, 2001, 59, 875-885.	2.3	20
15	Activation of Guanosine 5â€²-[Î³-³⁵S]thio-triphosphate Binding through M₁Muscarinic Receptors in Transfected Chinese Hamster Ovary Cell Membranes: 2. Testing the â€œTwo-Statesâ€•Model of Receptor Activation. Molecular Pharmacology, 2001, 59, 886-893.	2.3	14
16	Evidence that the lizard helospectin peptides are O-glycosylated. FEBS Journal, 2000, 267, 4556-4560.	0.2	6
17	Characterization of a novel VPAC1 selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition. British Journal of Pharmacology, 2000, 130, 819-826.	5.4	9
18	Different Vasoactive Intestinal Polypeptide Receptor Domains Are Involved in the Selective Recognition of Two VPAC2-Selective Ligands. Molecular Pharmacology, 1999, 56, 1280-1287.	2.3	38

#	Article	IF	Citations
19	Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. FEBS Journal, 1999, 265, 449-456.	0.2	25
20	Evidence for Multiple Rat VPAC1 Receptor States with Different Affinities for Agonists. Cellular Signalling, 1999, 11, 691-696.	3.6	7
21	Kinetics versus equilibrium: the importance of GTP in GPCR activation. Trends in Pharmacological Sciences, 1999, 20, 477-481.	8.7	21
22	Properties of a Recombinant Human Secretin Receptor. Pancreas, 1999, 19, 51-55.	1.1	3
23	A Critical View of the Methods for Characterization of the VIP/PACAP Receptor Subclassesa. Annals of the New York Academy of Sciences, 1998, 865, 157-163.	3.8	14
24	Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. European Journal of Pharmacology, 1998, 354, 105-111.	3.5	30
25	Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin. FEBS Letters, 1998, 424, 207-210.	2.8	46
26	Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. European Journal of Pharmacology, 1998, 348, 95-99.	3.5	25
27	The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP 2 Receptor Subclass. Peptides, 1997, 18, 403-408.	2.4	162
28	Development of High Affinity Selective VIP1 Receptor Agonists. Peptides, 1997, 18, 1539-1545.	2.4	190
29	In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor. Peptides, 1997, 18, 1555-1560.	2.4	173
30	Mutational Analysis of Extracellular Cysteine Residues of Rat Secretin Receptor Shows that Disulfide Bridges are Essential for Receptor Function. FEBS Journal, 1997, 246, 173-180.	0.2	44
31	Seven Helix Receptors are Enzymes Catalysing G Protein Activation. What is the Agonist Kact?. Journal of Theoretical Biology, 1997, 187, 15-37.	1.7	19
32	The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides, 1996, 17, 825-829.	2.4	78
33	Interaction of Amino Acid Residues at Positions 8-15 of Secretin with the N-Terminal Domain of the Secretin Receptor. FEBS Journal, 1996, 239, 349-355.	0.2	36
34	Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. European Journal of Pharmacology, 1995, 288, 259-267.	2.6	46
35	The (S)-(+)-enantiomer of dimethindene: a novel M2-selective muscarinic receptor antagonist. European Journal of Pharmacology, 1995, 286, 229-240.	3.5	24
36	Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regulatory Peptides, 1994, 54, 397-407.	1.9	58

#	Article	IF	Citations
37	(Hydroxymethyl)diphenyl(piperidinoalkyl)silane des Typs (HOCH2)(C6H5)2Si(CH2)nNC5H10(n=2,3) und deren Methoiodide: Synthese, Struktur und antimuscarinische Eigenschaften / (Hydroxymethyl)diphenyl(piperidinoalkyl)silanes of the Type (HOCH2)(C6H5)2Si(CH2)nNC5H10(n = 2,3) and their Methiodides: Synthesis, Structure and Antimuscarinic Properties. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 1994, 49, 898-910.	0.7	8
38	Characterization and regulation of the expression of scyllatoxin (Leiurotoxin I) receptors in the human neuroblastoma cell line NB-OK 1. FEBS Letters, 1991, 285, 271-274.	2.8	4
39	Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. European Journal of Pharmacology, 1990, 189, 135-142.	2.6	24
40	Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. European Journal of Pharmacology, 1989, 168, 71-80.	3.5	101
41	Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes. European Journal of Pharmacology, 1988, 155, 167-170.	3.5	37
42	A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Letters, 1988, 228, 351-355.	2.8	54
43	CCK and gastrin inhibit adenylate cyclase activity through a pertussis toxin-sensitive mechanism in the tumoral rat pancreatic acinar cell line AR 4-2J. FEBS Letters, 1988, 242, 61-64.	2.8	34
44	80% of muscarinic receptors expressed by the NB-OK 1 human neuroblastoma cell line show high affinity for pirenzepine and are comparable to rat hippocampus M1 receptors. FEBS Letters, 1988, 226, 287-290.	2.8	32
45	Vasoactive Intestinal Peptide Receptors in Pancreas and Liver. Structure-Function Relationship. Annals of the New York Academy of Sciences, 1988, 527, 238-256.	3.8	18
46	Effect of freezing on the coupling of VIP receptors to adenylate cyclase in rat liver membranes. Life Sciences, 1988, 42, 505-510.	4.3	5
47	Different antagonist binding properties of rat pancreatic and cardiac muscarinic receptors. Life Sciences, 1987, 41, 2235-2240.	4.3	25
48	[d-Phe4]Peptide histidine-isoleucinamide ([d-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes. FEBS Journal, 1987, 165, 243-249.	0.2	16
49	Secoverine is a non-selective muscarinic antagonist on rat heart and brain receptors. European Journal of Pharmacology, 1986, 127, 17-25.	3.5	19
50	Alterations of rat cardiac adenylate cyclase activity with age. European Journal of Pharmacology, 1986, 126, 91-95.	3.5	10
51	Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas. Peptides, 1986, 7, 53-59.	2.4	22
52	Effector mechanisms of peptides of the VIP family. Peptides, 1986, 7, 101-107.	2.4	22
53	Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes. FEBS Journal, 1986, 159, 45-49.	0.2	47
54	In Vitro Effects of Gallamine on Dissociation Kinetics of (3H) N-Methylscopolamine and (3H) Pirenzepine from Rat Brain Muscarinic Receptors. Journal of Receptors and Signal Transduction, 1986, 6, 47-61.	1.2	11

#	Article	IF	Citations
55	Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2as a VIP Antagonist*. Endocrinology, 1985, 116, 2643-2649.	2.8	154
56	Secretin-induced changes in rate, contractility and adenylate cyclase activity in rat heart atria. Pflugers Archiv European Journal of Physiology, 1984, 401, 1-5.	2.8	13
57	Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom. FEBS Letters, 1984, 166, 273-276.	2.8	68
58	Evidence that helodermin, a newly extracted peptide from Gila monster venom, is a member of the secretin/VIP/PHI family of peptides with an original pattern of biological properties. FEBS Letters, 1984, 166, 277-282.	2.8	57
59	Pancreatic secretory factor (PSF), a protein from Gila monster venom stimulating enzyme secretion from rat pancreatic acini. FEBS Letters, 1984, 166, 283-287.	2.8	9
60	Specific labelling by [125 I]helodermin of high-affinity VIP receptors in rat liver membranes. FEBS Letters, 1984, 172, 55-58.	2.8	45
61	Importance of disulfide bonds in receptors for vasoactive intestinal peptide and secretin in rat pancreatic plasma membranes. Biochimica Et Biophysica Acta - Biomembranes, 1984, 773, 271-278.	2.6	44
62	Effects of verapamil on the binding properties of rat heart muscarinic receptors: Evidence for an allosteric site. Biochemical and Biophysical Research Communications, 1984, 121, 340-345.	2.1	35
63	Inhibition of Forskolin-stimulated cardiac adenylate cyclase activity by short-chain alcohols. FEBS Letters, 1983, 154, 205-208.	2.8	18
64	Similarities of the Guanine Nucleotide Binding Sites Responsible for Adenylate Cyclase Activation and Carbamylcholine Binding Inhibition in Rat Heart Membranes. Protides of the Biological Fluids; Proceedings of the Colloquium, 1982, 29, 381-384.	0.1	2
65	Heterogeneity of Vip-Secretin Receptors in three Rat Tissues. Protides of the Biological Fluids; Proceedings of the Colloquium, 1982, 29, 509-512.	0.1	1
66	Stimulation by ionophore A23187and carbamylcholine of prostaglandins release from the thyroid glandin vitro. Archives Internationales De Physiologie Et De Biochimie, 1977, 85, 1031-1032.	0.2	5
67	Biological Recognition of Enantiomeric Silanes and Germanes: Syntheses and Antimuscarinic Properties of the Enantiomers of the Si/Ge Analogues Cyclohexyl(hydroxymethyl)phenyl(2-Piperidinoethyl)silane and -Germane and Their Methiodides. , 0, , 231-236.		0
68	Biological Recognition of Enantiomeric Silanes and Germanes: Syntheses and Antimuscarinic Properties of the Enantiomers of the Si/Ge Analogues Cyclohexyl(hydroxymethyl)phenyl(2-Piperidinoethyl)silane and -Germane and Their Methiodides. , 0, , 231-236.		0